Oragenics, Inc. announced the appointment of Ms. Kimberly M. Murphy, member of the Board of Directors, as President effective June 23, 2022. Ms. Murphy brings more than 25 years of vaccine industry experience at leading pharmaceutical companies including serving as a key leader in the successful US and Global launch of Merck's HPV/Gardasil Franchise. Ms. Murphy joined Oragenics' Board of Directors in 2020.

Most recently Ms. Murphy served as Vice President of the Influenza Franchise and Global Vaccine Commercialization Leader at GSK, with responsibility for the global influenza vaccines business and also served as Vice President and Global Marketing Head for GSK's shingles vaccine, SHINGRIX. Earlier Ms. Murphy was Vice President and Lead for the North America Vaccines Integration Planning Team where she integrated GSK's acquisition of Novartis AG's vaccine division and served as Vice President of U.S. Vaccines Customer Strategy and as Senior Director of U.S. Influenza Portfolio Strategy. She also had distinguished vaccine leadership careers at Merck & Co., Inc. and Novartis.

Ms. Murphy currently serves as a Director of Blue Water Vaccines, Inc. and as Chairperson of Clarus Therapeutics Holdings Inc. She previously served in Board and advisory roles for a privately held vaccine development company, the Biotechnology Industry Organization, the Biodefense Advisory Council and the Saint Joseph's University Pharmaceutical & Healthcare Marketing MBA Program. Ms. Murphy holds a BA from Old Dominion University and an MBA from Saint Joseph's University, and completed the Marketing Excellence Program at the Wharton School of the University of Pennsylvania.